

CITATION REPORT

List of articles citing

Unmet needs in rheumatoid arthritis

DOI: 10.1186/ar1736

Arthritis Research and Therapy, 2005, 7 Suppl 3, S2-8.

Source: <https://exaly.com/paper-pdf/39506304/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. <i>Future Rheumatology</i> , 2006 , 1, 293-302		
20	Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1497-502	2.4	16
19	Outcomes in rheumatoid arthritis: incorporating the patient perspective. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 101-5	5.3	23
18	Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. <i>European Journal of Pharmacology</i> , 2009 , 613, 155-62	5.3	44
17	Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R43	5.7	35
16	LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 929-39		390
15	Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. <i>Journal of Rheumatology</i> , 2010 , 37, 692-703	4.1	81
14	Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. <i>Arthritis and Rheumatism</i> , 2011 , 63, 455-66		38
13	A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. <i>Results in Immunology</i> , 2012 , 2, 204-11		30
12	PI3 kinase β is a key regulator of synoviocyte function in rheumatoid arthritis. <i>American Journal of Pathology</i> , 2012 , 180, 1906-16	5.8	82
11	Compound K, a Metabolite of Ginsenosides, Attenuates Collagen-induced Arthritis in Mice. <i>Journal of Rheumatic Diseases</i> , 2015 , 22, 154	1.2	3
10	APLAR rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 685-713	2.3	93
9	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 291-304	5.3	84
8	Association of rs182429 variant in TAGAP with rheumatoid arthritis in Pakistani population. <i>Meta Gene</i> , 2017 , 14, 59-63	0.7	
7	An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis. <i>Vaccine</i> , 2017 , 35, 4048-4056	4.1	11
6	T cell activation Rho GTPase activating protein (TAGAP) is upregulated in clinical and experimental arthritis. <i>Cytokine</i> , 2018 , 104, 130-135	4	7
5	TGF- β +869C/T polymorphism increases susceptibility to rheumatoid arthritis in North Indian population. <i>Clinical Rheumatology</i> , 2020 , 39, 2881-2888	3.9	2

4	Amelioration of autoimmunity and inflammation by zinc oxide nanoparticles in experimental rheumatoid arthritis. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 394, 1975-1981	3.4	2
3	Abatacept in the treatment of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 365-75	2.9	31
2	Patient-centered approaches for patients with systemic autoimmune rheumatic diseases: development and evolution.. <i>Expert Review of Clinical Immunology</i> , 2022 , 1-9	5.1	
1	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- γ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 1-9	3.8	1